| Literature DB >> 25643932 |
Su-ying Zhao1, Dong-yang Jiang2, Peng-cheng Xu3, Yi-kai Zhang4, Heng-fang Shi5, Hui-ling Cao6, Qian Wu7,8,9.
Abstract
BACKGROUND: To investigate the drug resistant gene profiles and molecular typing of Acinetobacter baumannii isolates collected from clinical specimens in a comprehensive hospital, Jiangsu province.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25643932 PMCID: PMC4328433 DOI: 10.1186/s12941-015-0066-4
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
The sequence of primers used in this study
|
|
|
|
|
|---|---|---|---|
| blaOXA-51-like | OXA-51-like F | TAATGCTTTGATCGGCCTTG | 353 |
| OXA-51-like R | TGGATTGCACTTCATCTTGG | ||
| blaOXA-23-like | OXA-23-like F | GATCGGATTGGAGAACCAGA | 501 |
| OXA-23-like R | ATTTCTGACCGCATTTCCAT | ||
| blaOXA-24-like | OXA-24-like F | TTCCCCTAACATGAATTTGT | 1024 |
| OXA-24-like R | GTACTAATCAAAGTTGTGAA | ||
| blaOXA-58-like | OXA-58-like F | TGGCACGCATTTAGACCG | 507 |
| OXA-58-like R | AAACCCACATACCAACCC | ||
| blaIMP-1 | IMP F | CTACCGCAGCAGAGTCTTTAC | 587 |
| IMP R | AACCAGTTTTGCCTTACCAT | ||
| blaVIM-1 | VIM F | ATTCCGGTCGGMGAGGTCCG | 633 |
| VIM R | GAGCAAGTCTAGACCGCCCG | ||
| blaSHV | SHV F | GGTTATGCGTTATATTCGCC | 865 |
| SHV R | TTAGCGTTGCCAGTGCTC | ||
| blaGES | GES F | ATGCGCTTCATTCACGCAC | 392 |
| GES R | ATTTGCTGATTTCGCTCGG | ||
| blaTEM | TEM F | ATCAGCAATAAACCAGC | 516 |
| TEM R | CCCCGAAGAACGTTTTC | ||
| 16S rRNA | 16S-8F | AGAGTTTGATCCTGGCTCAG | 1499 |
| 16S-1493R | ACGGCTACCTTGTTACGACTT | ||
| blaAmpC | AmpC F | CGACAGCAGGTGGAT | 513 |
| AmpC R | GGTTAAGGTTGGGATG | ||
| aac(6′)-Ib | aac(6′)-Ib F | ATGACTGAGCATGACCTTGC | 519 |
| aac(6′)-Ib R | TTAGGCATCACTGCGTGTTC | ||
| aac(6′)-II | aac(6′)-II F | GAGCGACCGACTCTTGATG | 326 |
| aac(6′)-II R | CGTATGGCTCGATGGTTGTT | ||
| CarO | CarO F | CAGAGCCTTTTCCTAAGGAGAA | 916 |
| CarO R | GCTCACCTGATGCTGACATTAA | ||
| qacΔE 1-sul1 | qacEΔ1-sul1 F | TAGCGAGGGCTTTACCTAAGC | 300 |
| qacEΔ1-sul1 R | ATTCAGAATGCCGAACACCG | ||
| intl 1 | intl 1 F | ACGAGCGCAAGGTTTGGT | 565 |
| intl 1 R | GAAAGGTCTGGTCATACATG |
Age distribution between patients with multidrug-resistant and non-multidrug-resistant
|
|
|
|
|
|---|---|---|---|
| <40 | 2 | 0 | 2 |
| 40~ | 2 | 2 | 4 |
| 50~ | 1 | 6 | 7 |
| 60~ | 13 | 9 | 22 |
| 70~ | 25 | 21 | 46 |
| >80 | 21 | 18 | 39 |
| Total | 64 | 56 | 120 |
Ward distribution between patients with multidrug-resistant and non-multidrug-resistant
|
|
|
|
|
|---|---|---|---|
| Respiration | 6 | 20 | 26 |
| ICU | 19 | 1 | 20 |
| Emergency | 13 | 1 | 14 |
| Geriatrics | 5 | 8 | 13 |
| Nephrology | 2 | 6 | 8 |
| Neurology/neurosurgery | 12 | 2 | 14 |
| Cardiology | 4 | 4 | 8 |
| Others* | 3 | 14 | 17 |
*Others: Department of wounds, rheumatology, Chinese Acupuncture, E.N.T., oncology, gastroenterology, hematology and cardiothoracic surgery.
Antibiotics resistance of multidrug-resistant isolates
|
|
| |
|---|---|---|
|
|
| |
| Ampicillin | 51 | 78.5 |
| Cefotetan | 50 | 76.9 |
| Cefazolin | 51 | 78.5 |
| Ceftriaxone | 49 | 75.4 |
| Imipenem | 60 | 92.3 |
| Gentamicin | 57 | 87.7 |
| Levofloxacin | 52 | 80.0 |
| Furadantin | 51 | 78.5 |
| Ampicillin/sulbactam | 61 | 93.8 |
| Piperacillin/tazobactam | 58 | 89.2 |
| Ceftazidime | 60 | 92.3 |
| Cefepime | 60 | 92.3 |
| Aztreonam | 60 | 92.3 |
| Ciprofloxacin | 64 | 98.5 |
| Cotrimoxazole | 53 | 81.5 |
| Tobramycin | 53 | 81.5 |
| Cefoperazone | 14 | 21.5 |
| Cefoperazone/sulbactam | 12 | 18.5 |
The detective rate of drug-resistant genes between groups
|
|
|
|
| ||
|---|---|---|---|---|---|
|
|
|
|
| ||
| blaOXA-51-like | 91.7 | 64 | 100.0 | 46 | 82.1 |
| blaOXA-23-like | 83.3 | 58 | 90.6 | 42 | 75.0 |
| blaOXA-24-like | 0 | 0 | 0 | 0 | 0 |
| blaOXA-58-like | 0.8 | 1 | 1.5 | 0 | 0 |
| blaIMP-1 | 5.0 | 2 | 3.1 | 4 | 7.1 |
| blaVIM-1 | 85.8 | 61 | 95.3 | 42 | 75 |
| blaTEM | 25.8 | 16 | 25.0 | 15 | 26.8 |
| blaSHV | 66.7 | 47 | 73.4 | 33 | 58.9 |
| blaGES | 3.3 | 1 | 1.6 | 3 | 5.4 |
| 16S rRNA | 100.0 | 65 | 100.0 | 55 | 100.0 |
| blaAmpC | 75.0 | 53 | 82.8 | 37 | 66.1 |
| aac(6′)-Ib | 41.7 | 32 | 50.0 | 18 | 32.1 |
| aac(6′)-II | 2.5 | 1 | 1.6 | 2 | 3.6 |
| Loss of CarO | 64.2 | 43 | 67.2 | 34 | 60.7 |
| Intl 1 | 70.8 | 53 | 82.8 | 32 | 57.1 |
| qac∆E1-sul1 | 53.3 | 36 | 56.3 | 28 | 50.0 |
Figure 1Molecular typing of representative multidrug resistant isolates by PFGE. Participating wards, clone type, and source of the samples were also indicated. GE: Geriatrics; R: Respiration; C: Cardiology; E: Emergency; NEU: Neurology; W:wound; GA: Gastroenterol; NEP: Nephrology; HE: Hematology; UL: Urology; S:sputum; CF: cerebrospinal fluid; U:urine.
The distribution of clone strains in each ward
|
|
| |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| ICU | 6 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Respiration | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Neurology | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Emergency | 4 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Geriatrics | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others* | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
*Others refer to Department of Cardiology, Urology, Nephrology, Hematology, and Gastroenterology.